NCT05101746
Nitric Oxide Effect on Brain and Kidney in Pediatric Patients Undergoing Cardiopulmonary Bypass
Enrolling by Invitation
PHASE2Ages 0–1InterventionalTreatmentVanderbilt University Medical CenterInvestigator-initiated
~50 participants
Updated 2025-10-08 on ClinicalTrials.gov
What's tested:Nitric Oxide (NO) 20 part per million (ppm)Standard of care cardiopulmonary bypass
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Level of glial fibrillary acid protein (GFAP)
Measured over baseline to peak rewarming temperature of blood (approximately 3 hours)
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesTennessee1
Study leadership
- David P Bichell, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Level of glial fibrillary acid protein (GFAP)baseline to peak rewarming temperature of blood (approximately 3 hours)
GFAP will be measured via blood sample
- Level of neutrophil gelatinase-associated lipocalin (NGAL)baseline to 2 hours after CPB initiation (approximately 2 hours)
NGAL will be measured via blood sample